A
13.39
0.59 (4.61%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Alto Neuroscience, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
0.5
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | -5.0 |
| 技术平均移动指标 | 3.5 |
| 技术振荡指标 | 0.5 |
| 平均 | 0.50 |
|
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 7.48% |
| 机构持股比例 | 77.52% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Alpha Wave Global, Lp | 30 Sep 2025 | 3,707,757 |
| Armistice Capital, Llc | 30 Sep 2025 | 1,636,000 |
| Vestal Point Capital, Lp | 30 Sep 2025 | 950,000 |
| 72 Investment Holdings, Llc | 30 Sep 2025 | 667,778 |
| Alkeon Capital Management Llc | 30 Sep 2025 | 477,101 |
| Integral Health Asset Management, Llc | 30 Sep 2025 | 400,000 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 50.00 (HC Wainwright & Co., 273.41%) | 购买 |
| 中 | 25.00 (86.71%) | |
| 低 | 15.00 (Chardan Capital, 12.02%) | 购买 |
| 平均值 | 27.80 (107.62%) | |
| 总计 | 5 购买 | |
| 平均价格@调整类型 | 10.87 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| BTIG | 17 Nov 2025 | 27.00 (101.64%) | 购买 | 13.80 |
| Baird | 13 Nov 2025 | 22.00 (64.30%) | 购买 | 11.35 |
| 20 Oct 2025 | 16.00 (19.49%) | 购买 | 11.00 | |
| Jefferies | 12 Nov 2025 | 25.00 (86.71%) | 购买 | 14.20 |
| HC Wainwright & Co. | 24 Oct 2025 | 50.00 (273.41%) | 购买 | 11.00 |
| Chardan Capital | 29 Sep 2025 | 15.00 (12.02%) | 购买 | 4.01 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合